Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer

2 Aug 2017

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) inhibitors represent a promising strategy toward the treatment of triple-negative breast cancer (TNBC), which is often associated to genomic instability and/or BRCA mutations. However, clinical outcome is controversial and no benefits have been demonstrated in wild type BRCA cancers, possibly due to poor drug bioavailability and low nuclear delivery. In the attempt to overcome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28790402
DOI: 10.1038/s41598-017-07617-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancerPMID 28790402Read ↗

Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer.Semantic proximity Read ↗

Discovery of PARP1-PROTAC as novel strategy against PARP inhibitor resistance via promoting ferroptosis in mutant-p53 triple-negative breast cancerSemantic proximity Read ↗

Breaking the Iron Homeostasis: A “Trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP InhibitionSemantic proximity Read ↗

Red Blood Cell-derived Extracellular Vesicles enable Cisplatin and Cetuximab combined Therapy against Triple-Negative Breast CancerSemantic proximity Read ↗

Harnessing DNA Tetrahedral Nanoparticles: A Novel Strategy for Co- delivery of OTUD6B siRNA and DOX Against TNBC Growth and ProgressionSemantic proximity Read ↗

Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.Semantic proximity Read ↗

H‐Chain Ferritin: A Natural Nuclei Targeting and Bioactive Delivery NanovectorSemantic proximity Read ↗

Ferritin-Coated SPIONs as New Cancer Cell Targeted Magnetic NanocarrierSemantic proximity Read ↗

Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compoundsSemantic proximity Read ↗

Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of actionSemantic proximity Read ↗

pH-Sensitive Shell–Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative Breast CancerSemantic proximity Read ↗

DNA Nanoflower Enables Controlled Co-Delivery of Antisense Oligodeoxynucleotide and Doxorubicin for Anti-breast Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.